No Data
No Data
Express News | NanoViricides Shares Are Trading Higher After the Company Announced It Discussed Its Development Program for NV-387
NanoViricides Discusses Lead Program and Next Steps | NYSE-A:NNVC
NanoViricides Is Well Positioned With Its Clinical and Pre-Clinical Pipeline and Unique Host-Mimetic, Virus Killing, Technology Platform Intending To Revolutionize Treatment of Viral Infections
NanoViricides Hails Broad Potential of Lead Antiviral Drug as It Prepares to Begin First Phase II Trial | NYSE-A:NNVC
NanoViricides Reports Promising Results for NV-387 in Influenza A H3N2 Mouse Model | NYSE-A:NNVC
A Novel Broad-Spectrum Antiviral Against Influenza A Viruses, NV-387, Could Be an Important Weapon to Fight Bird Flu H5N1, Says NanoViricides
SHELTON, CT / ACCESSWIRE / June 24, 2024 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, comments that the ultra-broa